Johnson & Johnson Announces Permanent Billing Code for INLEXZO Gemcitabine Intravesical System
Johnson & Johnson confirmed that the Healthcare Common Procedure Coding System (HCPCS) J‑code J9183 has been permanently assigned for INLEXZO™ (gemcitabine intravesical system), effective April 1, 2026, which helps standardize billing and reimbursement for this bladder cancer therapy. The therapy is indicated for adult patients with BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ, offering a novel local delivery system of gemcitabine that addresses a treatment gap for patients ineligible for or who have failed BCG therapy. With the permanent code in place, physicians and payers have a clearer pathway for claims, potentially improving access and reducing administrative barriers for eligible patients. 
Johnson & Johnson Announces Permanent Billing Code for INLEXZO Gemcitabine Intravesical System